NGM Biopharmaceuticals, Inc. (NGM) Tops Q2 EPS by 4c

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) reported Q2 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $1.42 million versus the consensus estimate of $3.3 million.

For earnings history and earnings-related data on NGM Biopharmaceuticals, Inc. (NGM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15